In patients with hyperleukocytic AML, the presence of a FLT3-ITD mutation is associated with a significantly different 14-day survival (p = 0.007), whereas age and relative leukocyte reduction are not associated with any differences in early mortality. The gene discussed is FLT3; the disease is acute myeloid leukemia.